Want to see TIL full AI Analyst Report?
Top Page
Instil Bio
(NASDAQ:TIL)
Select Model
Select Model
Rating:46Neutral
Price Target:
$7.00
▼(-10.60% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, and negative free cash flow despite improvements) and a weak longer-term technical trend (below key moving averages). Valuation support is limited due to negative earnings, while the recent governance-related corporate event is a modest positive but not enough to offset fundamental risks.
Positive Factors
Low Leverage
Very modest debt relative to equity limits interest and refinancing pressure, giving Instil Bio greater flexibility to fund clinical development. Although the company remains loss-making, leverage is currently not the primary threat to financial stability.
Negative Factors
No Meaningful Revenue
Without recurring product or collaboration revenue, Instil Bio has limited visibility into future funding capacity and breakeven timing. The business remains dependent on successful clinical development, regulatory approval, and eventual commercialization of its candidates.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very modest debt relative to equity limits interest and refinancing pressure, giving Instil Bio greater flexibility to fund clinical development. Although the company remains loss-making, leverage is currently not the primary threat to financial stability.
Read all positive factors
Instil Bio (TIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$53.04M
Dividend YieldN/A
Average Volume (3M)7.77K
Price to Earnings (P/E)―
Beta (1Y)5.16
Revenue GrowthN/A
EPS Growth65.39%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.47
Shares Outstanding6,781,976
10 Day Avg. Volume7,946
30 Day Avg. Volume7,771
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.17
Revenue Forecast (FY)N/A
Instil Bio Business Overview & Revenue Model
Company Description
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. I...
How the Company Makes Money
Instil Bio is a clinical-stage biotechnology company and, as such, it generally does not generate recurring product sales revenue from commercialized therapies. Its ability to make money in the future is expected to come primarily from (a) success...
Instil Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -24.00K | -534.00K | 0.00 | 0.00 | -5.99M | 0.00 |
| EBITDA | -29.61M | -65.01M | -62.53M | -147.12M | -217.38M | -152.51M |
| Net Income | -30.28M | -71.37M | -74.14M | -156.09M | -223.18M | -156.79M |
Balance Sheet | ||||||
| Total Assets | 197.71M | 203.52M | 263.57M | 325.63M | 482.13M | 609.98M |
| Cash, Cash Equivalents and Short-Term Investments | 69.68M | 76.13M | 113.31M | 150.36M | 260.92M | 454.10M |
| Total Debt | 3.67M | 85.18M | 86.89M | 86.05M | 79.90M | 0.00 |
| Total Liabilities | 90.33M | 89.66M | 94.13M | 99.80M | 118.52M | 54.78M |
| Stockholders Equity | 107.38M | 113.87M | 169.44M | 225.83M | 363.61M | 555.20M |
Cash Flow | ||||||
| Free Cash Flow | -23.61M | -36.62M | -65.70M | -102.69M | -264.75M | -179.97M |
| Operating Cash Flow | -23.61M | -36.62M | -55.70M | -82.03M | -180.16M | -122.14M |
| Investing Cash Flow | 21.24M | 25.48M | 53.97M | 41.13M | 114.54M | -474.40M |
| Financing Cash Flow | 378.00K | 7.29M | 1.75M | 8.08M | 71.89M | 393.16M |
Instil Bio Technical Analysis
Positive
7.83
Price Trends
7.49
Positive
7.76
Positive
8.42
Negative
Market Momentum
0.08
Negative
59.59
Neutral
53.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Positive. The current price of 7.83 is above the 20-day moving average (MA) of 7.57, above the 50-day MA of 7.49, and below the 200-day MA of 8.42, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.59 is Neutral, neither overbought nor oversold. The STOCH value of 53.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TIL.
Instil Bio Risk Analysis
Instil Bio disclosed 70 risk factors in its most recent earnings report. Instil Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Instil Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $231.35M | -1.85 | -39.64% | ― | ― | -6.70% | |
48 Neutral | $276.55M | -1.63 | -90.30% | ― | ― | 48.20% | |
46 Neutral | $53.04M | -1.70 | -26.78% | ― | ― | 65.39% | |
45 Neutral | $381.53M | -1.54 | -87.95% | ― | -100.00% | 14.08% | |
42 Neutral | $243.06M | -0.49 | 187.62% | ― | -8.79% | -195.46% | |
37 Underperform | $23.37M | -0.36 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
TIL
Instil Bio
7.58
-15.40
-67.01%
ZNTL
Zentalis Pharmaceuticals
3.80
2.34
160.27%
NKTX
Nkarta
2.91
0.89
44.06%
ALXO
ALX Oncology Holdings
1.84
0.67
57.26%
SRZN
Surrozen
20.03
8.19
69.17%
TCRX
TScan Therapeutics
0.33
-1.51
-82.07%
Instil Bio Corporate Events
Executive/Board ChangesShareholder Meetings
Instil Bio Shareholders Back Directors and Auditor at Meeting
Positive
Jun 11, 2026
Instil Bio, Inc. reported that on June 11, 2026 it held its 2026 Annual Meeting of Stockholders, at which approximately 84.9% of outstanding common shares were present or represented by proxy. Shareholders elected George Matcham and Neil Gibson as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.